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Abstract
Background: The clinical development of a single encounter treatment for uncomplicated malaria has the potential to
significantly improve the effectiveness of antimalarials. Exploratory data suggested that the combination of artefenomel
and piperaquine phosphate (PQP) has the potential to achieve satisfactory cure rates as a single dose therapy. The
primary objective of the study was to determine whether a single dose of artefenomel (800 mg) plus PQP in ascending
doses is an efficacious treatment for uncomplicated Plasmodium falciparum malaria in the 'target' population of
children ≤ 5 years of age in Africa as well as Asian patients of all ages.
Methods: Patients in six African countries and in Vietnam were randomised to treatment with follow-up for 42–63
days. Efficacy, tolerability, safety and pharmacokinetics were assessed. Additional key objectives were to characterise the
exposure–response relationship for polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological
response at day 28 post-dose (ACPR28) and to further investigate Kelch13 mutations. Patients in Africa (n = 355) and
Vietnam (n = 82) were included, with 85% of the total population being children < 5 years of age.
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Results: ACPR28 in the per protocol population (95% confidence interval) was 70.8% (61.13–79.19), 68.4% (59.13–76.66)
and 78.6% (70.09–85.67) for doses of 800 mg artefenomel with 640 mg, 960 mg and 1440 mg of PQP respectively.
ACPR28 was lower in Vietnamese than in African patients (66.2%; 54.55–76.62 and 74.5%; 68.81–79.68) respectively.
Within the African population, efficacy was lowest in the youngest age group of≥ 0.5 to≤ 2 years, 52.7% (38.80–66.35).
Initial parasite clearance was twice as long in Vietnam than in Africa. Within Vietnam, the frequency of the Kelch13
mutation was 70.1% and was clearly associated with parasite clearance half-life (PCt1/2). The most significant tolerability
finding was vomiting (28.8%).
Conclusions: In this first clinical trial evaluating a single encounter antimalarial therapy, none of the treatment arms
reached the target efficacy of > 95% PCR-adjusted ACPR at day 28. Achieving very high efficacy following single dose
treatment is challenging, since > 95% of the population must have sufficient concentrations to achieve cure across a
range of parasite sensitivities and baseline parasitaemia levels. While challenging, the development of tools suitable for
deployment as single encounter curative treatments for adults and children in Africa and to support elimination
strategies remains a key development goal.
Trial registration: ClinicalTrials.gov, NCT02083380. Registered on 7 March 2014.
Keywords: Artefenomel, OZ439, Piperaquine, Single dose combination treatment, Pharmacokinetics, Dose–response,
modelling and simulation, Phase II B, Uncomplicated Plasmodium falciparum malaria, Children,
Background
Since 2000 the incidence of malaria has fallen by 41%
and mortality rates have declined by 62% globally, due
to increased deployment of new interventions including
artemisinin-based combination treatments and insecti-
cide treated bed nets (WHO 2016) [1]. However, des-
pite these gains, in 2015 there were 212 million new
cases and an estimated 429,000 malaria-related deaths,
with Africa continuing to bear the heaviest burden, ac-
counting for approximately 9 in 10 malaria cases and
deaths, the vast majority of which were in young chil-
dren [1]. The high death rate in young children is be-
lieved to be linked to low acquired immunity, coupled
with greater vulnerability to the infection. Since lower
immunity may mean that young children require higher
drug exposures than older patients to achieve cure, it is
important to tailor dose selection to this population.
Patients in Asia may also have lower immunity due to
low endemicity.
Numerous studies have suggested that in 'real-life' com-
munity settings, poor to moderate adherence to current
standard 3-day treatment regimens is common, and this
could impact morbidity and mortality as well as drive the
development of resistance, although definitive data are dif-
ficult to obtain [2–4]. Availability of a highly efficacious
'single encounter treatment' would be expected to im-
prove effectiveness of malaria treatment and delay selec-
tion of resistant parasites. An effective cure that can be
administered as a single treatment, directly observed if re-
quired, would also provide an important tool to support
malaria elimination efforts [5, 6]. Medicines for Malaria
Venture (MMV) and its partners have undertaken to de-
velop single dose treatments for malaria [7].
Exploratory clinical data suggested that artefenomel
(OZ439) plus piperaquine phosphate (PQP) in combin-
ation could be efficacious as a single encounter cure. Arte-
fenomel, a novel synthetic trioxolane, contains a similar
peroxidic pharmacophore to artemisinins and has demon-
strated rapid parasite clearance in patients, with a median
parasite reduction ratio at 24 h (log10) post-treatment
(PRR24) for Plasmodium falciparum ranging from 0.9 to
1.88 [8]. PQP is a long-acting antimalarial currently mar-
keted in a fixed dose combination with dihydroartemisinin
(DHA), administered once daily for 3 days.
We report the results of the first clinical efficacy study
of the combination of artefenomel and PQP in a design
which allowed rapid progression from adult African pa-
tient to children ≤ 5 years of age and Asian patients of
all ages to ensure that dose finding for phase III is car-
ried out in populations most likely to require the highest
exposures to achieve cure. The study also employed in-
terim futility analyses in order to drop doses with a low
probability of success early.
Methods
Study objectives
The primary objective of the study was to determine
whether a single dose combination of artefenomel plus
PQP is an efficacious treatment for uncomplicated P.
falciparum malaria.
Secondary and exploratory objectives included deter-
mination of the incidence of recurrence, recrudescence
and new infection, estimation of parasite clearance kin-
etics and exploration of the relationship between
Kelch13 genotype and parasite clearance half-life
(PCt1/2) in Asian patients.
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An additional key exploratory objective was to charac-
terise the dose/exposure–response relationship for the
combination for the primary efficacy endpoint across the
patient population and to identify significant covariates
influencing efficacy. Safety, tolerability and pharmaco-
kinetics (PK) were also assessed. Details of the study ob-
jectives, design and endpoints are summarised in
Additional file 1: S1 Study protocol, Section 1 Study syn-
opsis and in more detail in Sections 4, 5.1 and 5.10
respectively.
The study was conducted at nine study sites across
six African countries, Benin (Cotonou), Burkina Faso
(Nanoro, Banfora and Niangoloko) [9, 10], Democratic
Republic of Congo (Kinshasa) [11], Gabon (Libreville,
Lambaréné) [12], Mozambique (Manhiça) [13] and
Uganda (Tororo) [14], and four sites in Vietnam
(Quang tri, Gia Lai, Khanh Hoa, Binh Phuoc) [15].
Malaria prevalence is hyperendemic to holoendemic,
and transmission is perennial in all sites with seasonal
variation. Drug resistance of P. falciparum against
chloroquine and sulfadoxine-pyrimethamine is wide-
spread at all African sites, and evidence of artemisinin
resistance was confirmed at the Vietnamese sites [16].
Study design, participants and interventions
This was a randomised, double-blind, single dose
study to investigate the efficacy, safety, tolerability
and PK of artefenomel 800 mg in loose combination
with three doses of PQP (640, 960, 1440 mg) in male
and female patients aged ≥ 6 months to < 70 years
(body weight ≥ 5 kg to ≤ 90 kg) with uncomplicated P.
falciparum malaria. The artefenomel dose of 800 mg
was expected to deliver close to the maximum well-
tolerated exposure, and PQP doses were selected to
span a range of adequate clinical and parasitological
response at day 28 (ACPR28) values, with the highest
dose estimated to give a mean maximum placebo
corrected change from baseline QTcF of 18 ms [17].
Patients presenting with microscopically confirmed P.
falciparum mono-infection in the range 1000 to 100,000
asexual parasites/μL of blood, and with fever (axillary
temperature ≥ 37.5 °C) or history of fever in the preced-
ing 24 h, were included following their submittal of writ-
ten informed consent, and all eligible patients were
randomised via an Interactive Web Response System
(IWRS) in a ratio of 1:1:1 to one of the three treatment
arms (see supplementary material). Important exclusion
criteria were the presence of severe malaria (according
to the WHO definition [18]), haemoglobin below 8 g/dL,
exclusions relating to cardiac and hepatic safety and
prior antimalarial treatment within specified time
frames. Full inclusion/exclusion criteria are given in
Additional file 1: S1 Study protocol, Sections 1 Study
synopsis and 6 Selection of patients.
The study was initiated in patients aged > 15 years,
and following review of safety data by an Independent
Safety Monitoring Board (ISMB), sequentially younger
patients were recruited in a step-down procedure de-
scribed in Additional file 1: S1 Study protocol, Section
6.5.2 and illustrated in Figure 1 (S1 Study protocol),
Step-down procedure. The aim was to recruit a popula-
tion predominantly of African children ≤ 5 years of age
and also to include Asian patients (the most important
target populations). Patient recruitment and follow-up
were conducted between July 2014 and August 2015.
Fasted patients ≥ 35 kg received artefenomel 800 mg in
loose combination with PQP doses of 640, 960 or
1440 mg at day 0. Patients who weighed < 35 kg received
body weight-adjusted doses [19] within weight bands
predicted to achieve similar exposure ranges to pa-
tients ≥ 35 kg. The dose for a given weight band was ad-
justed by scaling clearance allometrically, using the
relationship CL = (body weight/70)0.75. Artefenomel was
administered as a suspension formulation containing α-
tocopherol polyethylene glycol (TPGS). PQP was in-
cluded in the suspension (for patients < 24 kg) or was
administered as separate tablets (patients ≥ 24 kg), with
blinding maintained by administering matching placebo
tablets. For the lowest weight band the dosing volume
was 75 mL (plus 2× 15 mL rinses). Patients who vomited
within 5 min of start of dosing were re-dosed once.
Details of study drug treatments and administration are
given in Additional file 1: S1 Study protocol, Section 10
Treatment.
Following drug administration, patients were followed
for 42 days or 63 days at some centres (patients were
consented separately for days > 42 to 63). Patients
remained in the clinical unit for a minimum of 48
(African patients > 5 years old) or 72 h (African pa-
tients ≤ 5 years old and all Asian patients) and were dis-
charged provided parasite and fever clearance had been
achieved. Patients returned for assessment on days 3, 5,
7, 10, 14, 21, 28, 42 and 63 at selected centres. Blood
films (thick and thin) were prepared and axillary tem-
peratures were measured at screening/pre-dose, 6, 12,
18, 24, 30, 36, 48, 72 h and days 5, 7, 10, 14, 21, 28, 42
and 63. Assessments for safety included haematology,
clinical chemistry, urinalysis and a triplicate 12-lead
electrocardiogram (ECG). Clinical assessments were
taken according to the schedule presented in detail in
Additional file 1: S1 Study protocol, Section 2 Schedule
of assessments.
For screening, thick blood films were stained with 10%
Giemsa for 10 min, and thick and thin films for baseline
to follow-up were stained with 2% Giemsa for 30 min.
Expert microscopists determined parasite densities and
examined thick blood films for parasites and thin blood
films for non-falciparum infections. A second
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microscopist, blinded to initial readings, re-read all
slides, and a third resolved discrepant readings. A slide
was considered negative in the absence of asexual para-
sites per 1000 counted leukocytes using a 100× magnifi-
cation oil immersion objective. Parasite density was
calculated as follows: (number of counted parasites/
counted leukocytes) × most recent absolute leukocyte
count per microliter. Details of additional methods are
given in the supplementary material.
Analysis populations
The intention to treat (ITT) and safety analysis sets were
identical and included all patients who provided informed
consent, received the study drug (entire or partial dose)
and had a confirmed positive blood film for P. falciparum
asexual parasitaemia at inclusion. The ITT subset defined
for the Kaplan–Meier (KM) estimates of recurrence, re-
crudescence and new infection rate included only those
who consumed the entire dose.
The per protocol (PP) set was the primary analysis
set and included all patients comprising the ITT set
who consumed the entire dose and were without
major protocol deviations. The modified PP analysis
set in addition excluded patients who vomited be-
tween > 5 min and ≤ 4 h after start of drug administra-
tion. Patients could be excluded from a population for
more than one reason (see Fig. 1). The PK population
included all patients in the ITT set with at least one
evaluable PK sample after treatment administration.
Ethical considerations
The study (MMV_OZ439_13_003) conformed to the
Declaration of Helsinki and Standard Operating Proce-
dures that meet current regulatory requirements and
guidelines established by the International Conference
on Harmonization for Good Clinical Practice in Clinical
Studies. It was approved by the relevant Independent
Ethics Committees (IECs), national Institutional Review
Boards and, where relevant, local regulatory authorities
at each of the participating sites (for more details see the
supplementary material). The study protocol was
registered and the study results are reported on Clinical-
Trials.gov (NCT02083380).
Endpoints
The primary efficacy endpoint was polymerase chain
reaction (PCR)-adjusted ACPR28 in the PP analysis
set. We also report the following secondary and ex-
ploratory endpoints: PCR-adjusted ACPR at day 42
(ACPR42) and day 63 (ACPR63) and crude ACPR at
days 28, 42 and 63 for the ITT and PP analysis sets and
Kaplan–Meier incidence rate of recrudescence over
63 days (ITT subset); in the PP analysis set, percentage
of patients achieving parasite clearance at 72 h post-
Fig. 1 Analysis sets and exclusions
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dose, PCt1/2, Kelch13 genotype and the relationship
between Kelch13 genotype and PCt1/2 are also
reported.
ACPR was defined according to the WHO [20] as ab-
sence of parasitaemia on day X, irrespective of axillary
temperature, in patients who did not previously meet
any of the criteria of early treatment failure (ETF), late
clinical failure (LCF) or late parasitological failure (LPF).
The definition of ETF was a slight modification of the
WHO definition [20] (see Additional file 2: S2 Statistical
analysis plan, Section 15 Efficacy outcomes). The deriv-
ation of crude (unadjusted) and PCR-adjusted ACPR for
both the ITT and PP populations (for details see
Additional file 2: S2 Statistical analysis plan, Section 15
Efficacy outcomes) and of re-emergence, recrudescence
and new infection was also done according to the princi-
ples set down by the WHO and MMV [20, 21]. The
PCR methodology was in accordance with the proce-
dures to identify parasite populations recommended by
the WHO and MMV [22]. Three polymorphic genetic
markers, MSP1, MSP2 and GluRP, were used to distin-
guish recrudescence from new infections, according to
WHO-recommended procedures and as previously de-
scribed by Snounou et al. [21, 23]. Recrudescence was
defined as at least one identical allele for each of the
three markers in the pre-treatment and post-treatment
samples. New infections were diagnosed when all alleles
for at least one of the markers differed between the two
samples. Kelch13 genotyping (baseline) was determined
by the method of the Pasteur Institute [24], PCt1/2 was
calculated using the WWARN calculator [25] and the
relationship between Kelch13 genotype and PCt1/2 was
explored by site and by mutation graphically, and sum-
mary statistics reported. Details of the derivation and
definitions of other endpoints are provided in Additional
file 2: S2 Statistical analysis plan, Section 15 Efficacy
outcomes).
Safety and tolerability endpoints included incidence of
adverse events (AEs) and serious AEs (SAEs), vital signs,
physical measurements, laboratory safety measurements,
liver function tests (LFT) increase, cases fulfilling the Hy's
law definition and ECG abnormalities including absolute
QTc value categorisation and change from baseline QTc.
Further details are given in Additional file 2: S2 Statistical
analysis plan, Section 16 Safety outcome.
Treatment emergent adverse events of special interest
(TEAESIs), requiring rapid reporting, were also defined
in the protocol to ensure careful monitoring:
1) Hepatic: Hy's law definition cases; any alanine
transaminase (ALT) or aspartate transaminase
(AST) ≥ 5 × the upper limit of the normal range
(ULN); any elevation in total bilirubin ≥ 2.5 × ULN
(> 35% direct); any AST or ALT ≥ 3 × ULN with the
appearance of fatigue, nausea, vomiting, right upper
quadrant pain or tenderness, fever, rash and/or
eosinophilia (eosinophil percent or count above the
ULN); or ALT ≥ 3 × ULN that persisted for > 4 weeks
2) Cardiac: QTcF prolongation from baseline of > 60 ms;
QTcF at any time; QTcF > 450 ms; T-wave liability or
T-wave morphologic changes during therapy; bundle
branch block; and any arrhythmia
3) Haematological: Haemoglobin (Hb) drop > 2 g/dL
from baseline; Hb drop < 5 g/dL; absolute neutrophil
count (ANC) < 1000/μL
4) Pregnancy.
Statistical considerations
The aim of the study was to determine whether any of
the treatment arms reached a target PCR-adjusted
ACPR28 of ≥ 95% (PP analysis set). The study was not
powered for comparison between dosing arms.
ACPR28 was categorised as Cure and Failure according
to the WHO method [20]. Descriptive statistics and a
95% Clopper–Pearson two-sided confidence interval
(CI) were constructed around the single binomial pro-
portion per treatment arm and for all treatment arms
combined. Similar analyses were performed for the
ITT and modified per protocol population (mPP) ana-
lysis sets across all days, and for crude ACPR. Descrip-
tive summary statistics were also produced for all
secondary and exploratory endpoints. Further details
can be found in Additional file 2: S2 Statistical analysis
plan, Section 15 Efficacy outcomes and Section 6.6
Statistical tests.
Trial simulations suggested that a treatment arm size
of 106 should be required if the dose combination is
effective [26]. Recruitment was to be capped at a
maximum of 150 patients from the target population
(patients ≤ 5 years old in Africa or patients of any age
in Asia) per treatment arm. The study design was
adaptive, allowing interim assessment of response for
the purpose of concluding futility after recruitment of
50 evaluable patients per arm (target population). Fu-
tility was to be concluded if the probability that
ACPR28 was ≤ 90% was greater than or equal to 0.3
[27]. Additionally, African patients > 5 years old were
recruited during the age step-down, and these patients
were included in the final analysis but not the interim
futility analysis. Further details are given in Additional
file 1: S1 Study protocol, Section 11 Statistical methods
and data management.
Pharmacokinetic analysis
In adult patients (weighing > 35 kg) blood samples for
pharmacological analysis were collected at 15 to 16 time
points: pre-dose, 2, 4, 6, 12, 24, 48, 72 h and days 5, 7,
10, 14, 21, 28, 42, 63. In paediatric patients the number
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was between 3 and 10 samples. Artefenomel and pipera-
quine PK data were analysed separately using non-linear
mixed effect modelling (population PK analysis) in
Monolix (version 4.3.3) or NONMEM (version 7.3 or
later) respectively. For artefenomel, additional data from
two mono-therapy clinical phase II studies in adult
Asian patients were included in order to extend the dose
range (100–1200 mg); see Additional file 3: S3 Pharma-
cokinetic analysis details.
Subsequently, exposures of artefenomel and pipera-
quine for each patient were derived from the individual
PK parameters estimated in the population PK analysis.
Maximum plasma concentration (Cmax), time to reach
maximum concentration (Tmax) and concentration on
day 7 (Cday7) were obtained from the simulated profiles,
and the area under the curve (AUC) extrapolated to in-
finity (AUCinf) was calculated directly from the esti-
mated PK parameters. More details are provided in
Additional file 3: S3 Pharmacokinetic analysis details.
Exposure–response analysis
The relationship of the binary outcome of ACPR28 re-
sponse to the estimated artefenomel and piperaquine
Cday7 and other covariates was evaluated in a logistic
regression model using the statistical software R (ver-
sion 3.2.2). Within the single dose setting of the study,
Cday7 is highly correlated with other exposure vari-
ables, such as AUCinf or Cday14. However, Cday7 was
preferred to allow future extrapolation to multi-dose
regimens as well for its scientific rationale (concentra-
tions of any given drug may be required to exceed the
minimum parasiticidal concentration for at least 7 days
to achieve full parasite clearance). Additional covariates
evaluated were presumed immunity status (low for
African patients ≤ 5 years and Asian patients of all
ages), region, baseline parasitaemia, age and Kelch13
genotype. All patients in the ITT set with ACPR28
values and exposure for both drugs were included in
the analysis. More details are provided in Additional file
4: S4 Exposure–response analysis details.
Dose–response simulations
The objective of the simulations was to evaluate the
dose–response relationship for single dose combination
treatment with artefenomel and PQP based on the de-
veloped population PK and exposure–response models.
The simulations were performed for a range of single
dose combination doses (for a TPGS formulation) for
the African population ≤ 5 years of age. Actual doses as-
sumed the same body weight bands and dose adjust-
ments applied to this study. For further details see
Additional file 4: S4 Exposure–response analysis details.
Results
Interim analysis
An interim futility analysis was carried out after recruit-
ment of approximately 50 evaluable patients from the
target population per treatment arm as planned. All
doses were concluded to have reached the futility criteria
(probability of ACPR28 < 90% was 0.9999); hence, the
study was stopped. Recruitment to the study continued
during the futility analysis process.
Final analysis
Analysis populations
The analysis populations are shown in Fig. 1.
Patient disposition and demographics
A total of 448 patients were randomised equally to the
three treatment groups (randomised set, Table 2), and
437, n = 355 in Africa and n = 82 in Asia (Vietnam) re-
ceived the study drug (ITT/safety set, Table 1). Demo-
graphics and patient characteristics by region are given
in Table 1.
Demographic characteristics were similar across treat-
ment arms and analysis sets. Age (and hence weight) dif-
fered by region due to the enrolment structure. For the
ITT/safety set, in Africa, 81.1% of patients were ≤ 5 years
old, whereas in Asia 96.3% were > 15 years old. No pa-
tients ≤ 5 years old were recruited in Asia. There was
also a difference in sex; 48.3% of patients in Africa and
93.9% in Asia were male.
Median baseline asexual parasitaemia across all treat-
ment arms was 12,913/μL (range 187/μL to 220,240/μL),
was similar in Asian and African patients ≤ 5 years,
13,140/μL (range 1065/μL to 123,080/μL) and 14,029/μL
(range 187/μL to 229,240/μL) respectively and was
slightly lower in African patients > 5 years, 9714/μL
(range 835/μL to 160,040 μL).
Of those randomised, 178 (39.7%) completed the study
up to day 42 (or 63) (Table 2). Of the 270 patients
(60.3%) prematurely discontinued from the study, the
majority (47.1%) were discontinued due to meeting the
multiple criteria to receive antimalarial rescue treatment,
either from failure to clear baseline parasitaemia (1.6%)
or from parasite recurrence (i.e. treatment failure;
45.5%). Thus, premature study discontinuation prior to
day 28 (and prior to day 42 or 63) is linked with the effi-
cacy endpoint ACPR.
Compliance
Protocol defined compliance; consumption of the total
volume of study drug without vomiting (or successful
re-dosing in the event of vomiting within 5 min of
dosing) was 65% in the African population and 91.5% in
the Asian population. Non-compliance was predomin-
antly due to vomiting, with an overall incidence of
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vomiting of 28.8% (35% in Africa and 7% in Asia).
Compliance and vomiting incidence were similar in the
African population across age. There were anecdotal re-
ports that, in some centres, young children were unable
to ingest the full study dose, despite a reported success
rate of administration of study drug (with or without
subsequent vomiting) of > 95% in all populations.
Efficacy: ACPR
Crude and PCR-adjusted ACPR results are reported in
Table 3 for the ITT analysis set. Re-emergence, crude
and PCR-adjusted ACPR results for the PP analysis set
are reported in Table 4.
For the primary analysis set (PP) and endpoint
(ACPR28), none of the treatment arms reached the tar-
get efficacy of ≥ 95% and there was no clear dose–re-
sponse relationship, although efficacy was highest for
PQP 1440 mg (78.6%; 95% CI 70.09–85.67) across the
populations (Table 4; Fig. 2b).
Efficacy in the mPP population (excluding patients
who vomited) was similar to that in the PP population;
e.g. for a PQP dose of 1440 mg, ACPR28 was (80.0%;
95% CI 69.92–87.90) across the populations.
ACPR28 appeared lower in Asian (Vietnamese) than
in African patients; thus, for all treatment arms com-
bined, ACPR28 was 66.2% (95% CI 54.6–76.6) and 74.5%
Table 1 Demographics and patient characteristics (safety set)
All patients 800:640 (N = 143) 800:960 (N = 148) 800:1440 (N = 146) Total (N = 437)
Africa Number (n) 116 121 118 355
Age (years) (derived) Median 3.30 3.20 2.90 3.10
(Min., max.) (0.5, 54.3) (0.8, 44.6) (0.5, 37.7) (0.5, 54.3)
> 15.0 years n (%) 15 (12.9) 16 (13.2) 14 (11.9) 45 (12.7)
> 5.0 to ≤ 15.0 years n (%) 7 (6.0) 7 (5.8) 8 (6.8) 22 (6.2)
> 2.0 to ≤ 5.0 years n (%) 69 (59.5) 72 (59.5) 70 (59.3) 211 (59.4)
≥ 0.5 to≤ 2.0 years n (%) 25 (21.6) 26 (21.5) 26 (22.0) 77 (21.7)
Male n (%) 56 (48.3) 63 (52.1) 70 (59.3) 189 (53.2)
Vietnam n 27 27 28 82
Age (years) (derived) Median 27.30 27.30 28.60 27.45
(Min., max.) (12.5, 48.5) (9.7, 60.0) (13.3, 57.6) (9.7, 60.0)
> 15.0 years n (%) 26 (96.3) 26 (96.3) 27 (96.4) 79 (96.3)
> 5.0 to ≤ 15.0 years n (%) 1 (3.7) 1 (3.7) 1 (3.6) 3 (3.7)
> 2.0 to ≤ 5.0 years n (%) 0 0 0 0
≥ 0.5 to≤ 2.0 years n (%) 0 0 0 0
Male n (%) 27 (100.0) 22 (81.5) 28 (100.0) 77 (93.9)
n number of patients in each category/%)
Table 2 Patient disposition (randomised set)
All patients 800:640 (N = 148) 800:960 (N = 151) 800:1440 (N = 149) Total (N = 448)
Treated n (%) 143 (96.6) 148 (98.0) 146 (98.0) 437 (97.5)
Completed n (%) 57 (38.5) 56 (37.1) 65 (43.6) 178 (39.7)
Premature study discontinuation n (%) 91 (61.5) 95 (62.9) 84 (56.4) 270 (60.3)
Primary reason for premature study discontinuation
Criteria met for established anti-malarial treatment n (%) 68 (45.9) 79 (52.3) 64 (43.0) 211 (47.1)
Study drug discontinued n (%) 0 4 (2.6) 3 (2.0) 7 (1.6)
Withdrawal of consent n (%) 9 (6.1) 3 (2.0) 7 (4.7) 19 (4.2)
Investigator’s opinion n (%) 1 (0.7) 1 (0.7) 0 2 (0.4)
Patient non-compliant n (%) 0 1 (0.7) 0 1 (0.2)
Adverse event n (%) 0 0 1 (0.7) 1 (0.2)
Lost to follow-up n (%) 5 (3.4) 3 (2.0) 3 (2.0) 11 (2.5)
Other n (%) 8 (5.4) 4 (2.6) 6 (4.0) 18 (4.0)
n number of patients in each category/%)
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(95% CI 7.81–79.7) respectively (Fig. 2a). In the African
population, efficacy was lowest in the youngest age
group (≥ 0.5 to ≤ 2 years), 52.7% (95% CI 38.8–66.4) for
all treatment arms combined (Fig. 2b).
In the PP population, recurrence in African and
Vietnamese patients was 37.0% and 31.6% respectively at
day 28, with all but one determined by PCR to be recru-
descence in the Vietnamese population, whereas in the
African population, approximately one third of recurring
parasites was determined to be a new infection at day 28.
In Asia, in the PP population, the number and percent-
age of recrudescences and new infections, with 95% CIs,
was 11/80 (13.8%; CI 7.07–23.27) and 0/80 at day 14, 18/
79 (22.8%; CI 14.10–33.60) and 0/79 at day 21, 23/79
(29.1%; CI 19.43–40.42) and 1/79 (1.3%; CI 0.03–6.85) at
day 28, 26/78 (33.3%; CI 23.06–44.92) and 1/78 (1.3%; CI
0.03–6.94) at day 42, and 27/75 (36.0%; CI 25.23–47.91)
and 2/75 (2.7%; CI 0.32–9.30) at day 63.
In Africa, in the PP population, the number and per-
centage of recrudescences and new infections, with 95%
CIs, was 34/325 (10.5%; CI 7.35–14.31) and 1/325 (0.3%)
at day 14, 57/321 (17.8%; CI 13.74–22.39) and 19/321
(5.9%; CI 3.60–9.09) at day 21, 61/319 (19.1%; CI 14.95–
23.87) and 32/319 (10.0%; CI 6.96–13.87) at day 28, 65/
313 (20.8%; CI 16.41–25.69) and 50/313 (16.0%; CI
12.09–20.51) at day 42, and 62/277 (22.4%; CI 17.61–
27.75) and 49/277 (17.7%; 13.38–22.70) at day 63.
Kaplan–Meier estimates of the fraction of patients with
recrudescence and new infection over time by region and
age group are presented in Figs. 3 and 4 respectively.
Parasite clearance and association with Kelch13 mutation
A regional difference in the percentage of patients who
cleared parasites by 72 h post-dose was evident, with
92.9% (95% CI 89.6–95.4) of African patients achieving
parasite clearance by 72 h post-dose compared with
35.0% (95% CI 24.7–46.5) in Vietnamese patients. There
was no clear difference in the percentage of patients
who cleared parasites across the different piperaquine
doses or in the African population > 5 years compared
with those ≤ 5 years.
The median time to 50%, 90% and 99% parasite clear-
ance was approximately twice as long in Asia compared
with Africa (e.g. time to 90% parasite clearance was 23.6
(interquartile range, IQR 16.20–29.10) h in Asian pa-
tients and 14.30 (IQR 10.90–17.60) h in African patients.
Initial clearance of parasites was rapid in the African
population. Median parasite clearance half-life (PCt1/2)
was calculated using the WWARN Parasite Clearance
Estimator (PCE), details of which are published [25].
PCt1/2 is the estimated time for parasitaemia to de-
crease by half, derived from the clearance rate constant
1/h. Parasite clearance values were reported only for re-
sults with R2 > 0.75. PCt1/2 was longer in Vietnam ver-
sus Africa (6.1 h [minimum 1.1, maximum 12.7] versus
3.5 h [minimum 1.2, maximum 7.7]). Within Vietnam,
PCt1/2 was similar across the four study centres.
A total of 20 known Kelch13 genotypes were tested
for (in Africa four new genotypes were identified at low
frequency, 0.3–1.7%: A578S, A626V, M562T, Y541F,
none associated with artemisinin resistance) [28]. In
Table 3 Crude and PCR-adjusted ACPR by day: ITT analysis set
800:640 (N = 143) 800:960 (N = 148) 800:1440 (N = 146) Total (N = 437)
Day 28
Crude ACPR n/r (%) 76/143 (53.1) 79/148 (53.4) 92/146 (63.0) 247/437 (56.5)
95% CIa [44.63; 61.53] [45.01; 61.61] [54.64; 70.85] [51.73; 61.23]
PCR-adjusted ACPR n/r (%) 77/143 (53.8) 82/148 (55.4) 95/146 (65.1) 254/437 (58.1)
95% CIa [45.32; 62.21] [47.02; 63.57] [56.75; 72.76] [53.34; 62.79]
Day 42
Crude ACPR n/r (%) 63/143 (44.1) 66/148 (44.6) 68/146 (46.6) 197/437 (45.1)
95% CIa [35.77; 52.59] [36.43; 52.98] [38.29; 55.01] [40.35; 49.88]
PCR-adjusted ACPR n/r (%)a 67/143 (46.9) 72/148 (48.6) 73/146 (50.0) 212/437 (48.5)
95% CIa [38.47; 55.37] [40.36; 56.99] [41.62; 58.38] [43.74; 53.31]
Day 63b
Crude ACPR n/r (%)a 50/136 (36.8) 49/140 (35.0) 58/135 (43.0) 157/411 (38.2)
95% CIa [28.67; 45.45] [27.14; 43.51] [34.48; 51.76] [33.48; 43.09]
PCR-adjusted ACPR n/r (%)a 50/136 (36.8) 54/140 (38.6) 59/135 (43.7) 163/411 (39.7)
95% CIa [28.67; 45.45] [30.47; 47.16] [35.19; 52.50] [34.90; 44.57]
n number of patients in each category achieving ACPR, r total number of patients in the relevant analysis set with a defined response of Cure or Failure,
N total number of patients in relevant analysis set
aClopper–Pearson
bPatients followed up to day 63 consented separately from the patients followed up to day 42; hence, total patient population is lower for day 63
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Table 4 Re-emergence, crude and PCR-adjusted ACPR by day: PP analysis set
800:640 (N = 139) 800:960 (N = 140) 800:1440 (N = 139) Total (N = 418)
Day 28
Re-emergence n/r (%) 48/129 (37.2) 56/136 (41.2) 39/133 (29.3) 143/398 (35.9)
Recrudescence n/r (%) 25/129 (19.4) 37/136 (27.2) 22/133 (16.5) 84/398 (21.1)
95% CIa [12.95; 27.26] [19.93; 35.50] [10.67; 23.97] [17.20; 25.45]
New infection n/r (%) 11/129 (8.5) 10/136 (7.4) 12/133 (9.0) 33/398 (8.3)
95% CIa [4.33; 14.75] [3.58; 13.11] [4.75; 15.23] [5.78; 11.45]
Indeterminate n/r (%) 3/129 (2.3) 0 0 3/398 (0.8)
Negative n/r (%) 2/129 (1.6) 1/136 (0.7) 0 3/398 (0.8)
Missing n/r (%) 7/129 (5.4) 8/136 (5.9) 5/133 (3.8) 20/398 (5.0)
Crude ACPR n/r (%) 74/129 (57.4) 77/136 (56.6) 89/133 (66.9)] 240/398 (60.3)
95% CIa [48.36; 66.03] [47.85; 65.09] [58.23; 74.83 [55.31; 65.14]
PCR-adjusted ACPR n/r (%) 75/106 (70.8) 80/117 (68.4) 92/117 (78.6) 247/340 (72.6)
95% CIa [61.13; 79.19] [59.13; 76.66] [70.09; 85.67] [67.58; 77.32]
Day 42
Re-emergence n/r (%) 59/127 (46.5) 64/134 (47.8) 56/130 (43.1) 179/391 (45.8)
Recrudescence n/r (%) 29/127 (22.8) 37/134 (27.6) 25/130 (19.2) 91/391 (23.3)
95% CIa [15.86; 31.12] [20.24; 36.00] [12.85; 27.07] [19.17; 27.78]
New infection n/r (%) 16/127 (12.6) 17/134 (12.7) 18/130 (13.8) 51/391 (13.0)
95% CIa [7.38; 19.65] [7.57; 19.53] [8.42; 21.00] [9.87; 16.79]
Indeterminate n/r (%) 3/127 (2.4) 1/134 (0.7) 3/130 (2.3) 7/391 (1.8)
Negative n/r (%) 3/127 (2.4) 1/134 (0.7) 0 4/391 (1.0)
Missing n/r (%) 8/127 (6.3) 8/134 (6.0) 10/130 (7.7) 26/391 (6.6)
Crude ACPR n/r (%) 61/127 (48.0) 65/134 (48.5) 67/130 (51.5) 193/391 (49.4)
95% CIa [39.09; 57.07] [39.79; 57.29] [42.62; 60.39] [44.30; 54.43]
PCR-adjusted ACPR n/r (%)a 65/100 (65.0) 71/108 (65.7) 72/100 (72.0) 208/308 (67.5)
95% CIa [54.82; 74.27] [55.99; 74.60] [62.13; 80.52] [61.99; 72.73]
Day 63b
Re-emergence n/r (%) 59/114 (51.8) 70/122 (57.4) 53/116 (45.7) 182/352 (51.7)
Recrudescence n/r (%) 29/114 (25.4) 37/122 (30.3) 23/116 (19.8) 89/352 (25.3)
95% CIa [17.75; 34.45] [22.33; 39.30] [13.00; 28.25] [20.83; 30.16]
New infection n/r (%) 15/114 (13.2) 20/122 (16.4) 16/116 (13.8) 51/352 (14.5)
95% CIa [7.56; 20.77] [10.31; 24.18] [8.09; 21.43] [10.98; 18.61]
Indeterminate n/r (%) 4/114 (3.5) 3/122 (2.5) 4/116 (3.4) 11/352 (3.1)
Negative n/r (%) 3/114 (2.6) 1/122 (0.8) 0 4/352 (1.1)
Missing n/r (%) 8/114 (7.0) 9/122 (7.4) 10/116 (8.6) 27/352 (7.7)
Crude ACPR n/r (%)a 48/114 (42.1) 48/122 (39.3) 57/116 (49.1) 153/352 (43.5)
95% CIa [32.92; 51.71] [30.62; 48.59] [39.74; 58.58] [38.22; 48.82]
PCR-adjusted ACPR n/r (%)a 48/83 (57.8) 53/90 (58.9) 58/84 (69.0) 159/257 (61.9)
95% CIa [46.49; 68.60] [48.02; 69.16] [58.02; 78.69] [55.63; 67.83]
n number of patients in each category achieving ACPR, r total number of patients in the relevant analysis set with a defined response of Cure or Failure,
N total number of patients in relevant analysis set
aClopper–Pearson
bPatients followed up to day 63 consented separately from the patients followed up to day 42; hence, total patient population is lower for day 63
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Vietnam, a high frequency of Kelch13 mutation was ob-
served (70.1%). Five mutations were detected, four of
which, C580Y, I543T, P553L and V568G, are defined ac-
cording to the WHO [28] as validated or candidate
markers for partial artemisinin resistance. The exception
is C469P, which is not known to be associated with
artemisinin resistance [28].
PCt1/2 appeared to be associated with Kelch13 geno-
type; median PCt1/2 values for C580Y and P553L, the
two most frequently occurring mutations, were 7.9
(N = 24; minimum 2.4, maximum 12.3 h) and 8.1 h
(N = 19; minimum 5.5, maximum 12.7) respectively,
versus 2.6 h (N = 19; minimum 1.4, maximum 5.4) for
wild type (WT) (Fig. 5). Mutations that were present
at a lower frequency (1/67, 1.5%) also had greater
PCt1/2 values; C469P (8.3 h), I543T (5.5 h) and
V568G (7.4 h). PCt1/2 in patients with Kelch13 WT
in Vietnam was similar to that in the African popula-
tion (Fig. 5).
Safety and tolerability
No deaths were reported. One TEAE of vomiting occur-
ring 19 min post-dose (treatment-related) was reported
to have led to study treatment discontinuation.
Six treatment emergent serious adverse events
(TESAEs) were reported in four patients. One patient
had severe anaemia (2 days post-dose), one patient had a
reversible haemoglobin drop < 5 g/dL (26 days post-
dose) and one presented with febrile convulsions (7 h
post-dose). One patient had three TESAEs, two of re-
versible grade 3 transaminase elevations and one of neu-
tropenia (28 days post-dose). None of these TESAEs led
to premature study discontinuation. Five of the six
TESAEs were considered to be potentially related to the
study treatment, the exception being that of febrile con-
vulsion which was considered not related. No AEs due
to drug-induced liver toxicity (Hy’s law or increase of
ALT/AST with clinical symptoms for more than 4 weeks)
were reported.
Fig. 2 Efficacy: PCR-adjusted ACPR28 in the PP population, a by region (all ages), b by age in African patients, percentage in each category with 95%
confidence intervals. The numbers presented above the bars are the percent ACPR28. The majority of treatment failures were late parasitological
failures (32.9% across the populations and treatment arms), with one early treatment failure in an African patient > 5 years (PQP 640 mg arm)
Fig. 3 Kaplan–Meier population at risk of recrudescence by region and age group over time (ITT subset). Note that the y-axis is expanded
(survival range 0.5–1.0) to clearly visualise the failure rates
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Table 5 gives the incidence of TEAEs occurring in ≥ 5%
of the study population up to 28 days post-dose, by Sys-
tem Organ Class. All events of transaminase elevations
were reversible, except in one subject who withdrew con-
sent, interrupting the liver function test follow-up.
The most frequently reported TEAESI was QT pro-
longation in ECG: 24 (16.8%), 37 (25.0%) and 38 (26.0%)
of patients in the PQP 640 mg, 960 mg and 1440 mg
treatment arms respectively. A first degree atrioventricu-
lar (AV) block reported as grade 1 at 48 h post-dose (PR
interval 226.33 ms, heart rate 55 beats per min and
QTcB and QTcF within the normal range) was reported
in one patient (PQP 640 mg). The event resolved at day
7 post-dose (PR interval 185 ms and heart rate 78 beats
per min). One patient (PQP 1440 mg) had a mild revers-
ible sinus bradycardia which resolved in 4 days. QTcF in-
crease from baseline of 30–60 ms occurred in 55
(38.7%), 59 (40.4%) and 71 (49.7%) and of > 60 ms in 8
(5.6%), 11 (7.5%) and 27 (18 .9%) of patients respectively
in the 640, 960 and 1440 mg PQP dosing arms. All but
one QTcF value was < 480 ms (QTc value = 501 ms).
One patient (PQP 1440 mg) experienced a reversible
TEAESI of hyperbilirubinaemia (total bilirubin > 2.5 ×
ULN) in the System Organ Class hepatobiliary disorders.
This event was associated with a TESAE of anaemia (Hb
drop > 2 g/dL from baseline). Other frequent TEAESIs
were neutrophil count decreased < 1000/μL (41 patients;
9.4%) and Hb decreased (drop > 2 g/dL from baseline or
Hb < 5 g/dL: 40 patients; 9.2%). The most significant tol-
erability finding was vomiting (28.8%) according to the
compliance data. The high rate of vomiting is thought to
be partly related to the 'high volume' TPGS formulation
used in the study (although the reason for the regional
difference in vomiting rate is unclear).
Fig. 4 Kaplan–Meier population at risk of new infection by region and age group over time (ITT subset). Note that the y-axis is expanded (survival
range 0.5–1.0) to clearly visualise the failure rates
Fig. 5 Association of parasite clearance half-life and Kelch13 Status (PP analysis set). Vietnam (blue circles), Africa (red circles), median (black line),
C580Y + P553L polyclonal infection. Note that the plot includes only patients with both genotyping and PCt1/2 results
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Pharmacokinetic results
The final artefenomel and piperaquine population PK
models, including details of the analysis and model diag-
nostics, are provided in Additional file 3: S3 Pharmaco-
kinetic analysis details.
The PK of both artefenomel and piperaquine in adult
and paediatric patients could be described by three com-
partment disposition models. All (apparent) clearance
and volume parameters were related to body weight allo-
metrically. Additional covariates identified for the PK of
artefenomel were vomiting, artefenomel dose and age. In
particular, relative bioavailability was a function of age; it
was 40% lower for a patient of 1 year versus 20 years of
age. For the PK of piperaquine, the only additional co-
variate identified was vomiting. No covariate effects of
region, age (for piperaquine), sex, protocol-defined non-
compliance or actual or adult equivalent PQP dose were
identified.
Individual artefenomel and piperaquine exposures were
estimated for 427 and 426 patients respectively (including
patients who vomited and were not successfully re-dosed).
Summaries of the individual estimated exposures by re-
gion and age group are provided in Additional file 3: S3
Pharmacokinetic analysis details). Cday7 is summarised
across region and age group in Fig. 6.
Geometric mean artefenomel exposure was lowest in
the African population 0.5 to ≤ 2 years of age (which in-
cludes body weight bands 5–14.9 kg). Thus, AUCinf and
Cday7 were 7.6 μg*h/mL (coefficient of variation, CV
105%) and 2.0 ng/mL (CV 147%) respectively compared
with 10.0 μg*h/mL (CV 111%) and 3.3 ng/mL (CV
141%) for African patients > 5 years. Asian patients >
5 years (all but one over 35 kg) had higher mean expo-
sures than the African patients; AUCinf of 16.9 μg*h/mL
(CV 66%) and Cday7 of 5.1 ng/mL (CV 95%) (Fig. 6a).
Artefenomel exposures and between-patient variability
were similar across the three PQP treatment arms.
Piperaquine exposures increased approximately propor-
tionally with dose, although there was considerable over-
lap between the treatment arms. Exposures tended to be
lower in the African population ≤ 2 years of age (including
body weight band 5–9.9 kg) and in the Asian population
(Fig. 6b). Exposures of artefenomel and piperaquine were
about 50% and 70% lower respectively in patients who
vomited relative to those who did not. See Additional file
3: S3 Pharmacokinetic analysis details for further details
and Additional file 4: S4 Exposure–response analysis de-
tails for two patient exposure examples.
Exposure–response relationship
When exploring the observed ACPR28 by artefenomel
exposure bins (categorical Cday7 ranges) rather than
dose, the relationship between exposure and ACPR28 is
clearly visible (Fig. 7). The relationship was different be-
tween the two regions but similar for the two African
age groups. Thus, in the Asian population, a lower
ACPR28 was achieved for the same artefenomel Cday7
compared with the African population. Both the region
effect and lack of age effect were confirmed in the subse-
quent statistical analysis (logistic regression).
Table 5 Incidence of treatment-emergent adverse events in ≥ 5% of study population up to day 28 post-dose (safety analysis set)
Artefenomel mg: PQP mg
System Organ Class Preferred term 800:640 (N = 143) 800:960 (N = 148) 800:1440 (N = 146) Total (N = 437)
At least 1 TEAE (n (%) E) 115 (80.4) 266 127 (85.8) 324 122 (83.6) 308 364 (83.3) 898
Infections and infestations (n (%) E) 74 (51.7) 102 76 (51.4) 106 63 (43.2) 82 213 (48.7) 290
Malaria 43 (30.1) 44 45 (30.4) 48 34 (23.3) 34 122 (27.9) 126
Bronchitis 13 (9.1) 16 13 (8.8) 19 10 (6.8) 11 36 (8.2) 46
Rhinitis 11 (7.7) 11 9 (6.1) 10 10 (6.8) 10 30 (6.9) 31
Plasmodium falciparum infection 9 (6.3) 9 10 (6.8) 10 7 (4.8) 7 26 (5.9) 26
Investigations (n (%) E) 58 (40.6) 75 68 (45.9) 100 70 (47.9) 95 196 (44.9) 270
Electrocardiogram QT prolonged 27 (18.9) 29 41 (27.7) 48 44 (30.1) 56 112 (25.6) 133
Neutrophil count decreased 18 (12.6) 18 11 (7.4) 11 12 (8.2) 13 41 (9.4) 42
Haemoglobin decreased 9 (6.3) 9 20 (13.5) 22 11 (7.5) 11 40 (9.2) 42
Gastrointestinal disorders (n (%) E) 31 (21.7) 39 47 (31.8) 60 44 (30.1) 54 122 (27.9) 153
Diarrhoea 11 (7.7) 12 21 (14.2) 21 20 (13.7) 20 52 (11.9) 53
Vomiting 14 (9.8) 14 20 (13.5) 20 16 (11.0) 16 50 (11.4) 50
Abdominal pain 5 (3.5) 5 8 (5.4) 9 12 (8.2) 13 25 (5.7) 27
General disorders and administration site conditions (n (%) E) 11 (7.7) 11 14 (9.5) 16 17 (11.6) 21 42 (9.6) 48
Pyrexia 5 (3.5) 5 12 (8.1) 13 9 (6.2) 11 26 (5.9) 29
N number of subjects affected (%), E number of events
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The relation between artefenomel and piperaquine
exposure and ACPR28 was described with a logistic re-
gression model. Details of the model, analysis and
model diagnostics are provided in Additional file 4: S4
Exposure–response analysis details. The analysis data
set comprised 348 patients.
The probability of achieving ACPR28 (pACPR) was
found to be a function of artefenomel and piperaquine
exposures, the baseline parasitaemia (p ≤ 0.0001) and
region (interaction between region and artefenomel
Cday7) (p = 0.002):
log
p
1−p
 
¼ 3:23þ 0:22  Cday7PQ þ 0:73 − 0:59 if Asia½ ð Þ
Cday7OZ−1:27  log10 BaseParð Þ þ 0:46 if Asia½ 
where p is the probability of ACPR28 and BasePar is the
baseline parasitaemia (parasites/μL).
There was no statistically significant influence of either
Kelch13 genotype or age on pACPR, and (once region
was in the model) there was no additional influence of
presumed immunity status. In addition, no interaction
between the exposures of the two drugs was identified.
Three-dimensional (3D) graphical representations of
the exposure–ACPR28 model are shown in Fig. 8 for
African and Vietnamese patients, assuming a baseline
parasitaemia of 10,000 parasites/μL. These plots show
that both artefenomel and piperaquine exposure (Cday7)
contribute to efficacy (ACPR28) in a concentration-
dependent manner, and that this relationship is different
for African versus Vietnamese patients; that is, higher
artefenomel exposure (but not higher piperaquine
exposure) is required to achieve the same ACPR28 in
Vietnamese (Asian) versus African patients (see the
equation).
This difference in sensitivity to artefenomel (about five
times lower in Asian versus African patients) is illus-
trated by the difference in the isoboles plotted in Fig. 9
(red versus blue isoboles).
For example, if each drug were administered by itself
(Cday7 = 0 for the partner drug), assuming a baseline
parasitaemia of 100,000 parasites/μL in African pa-
tients, an artefenomel Cday7 of 8 ng/mL would be re-
quired for a 0.95 probability of achieving ACPR28,
compared to 40 ng/mL in Asian patients. For each pre-
sented scenario, any exposure combination of artefeno-
mel and piperaquine to the right of the isobole lines is
associated with > 0.95 probability of achieving ACPR28.
Fig. 6 Estimated Cday7 for artefenomel (a) and PQP (b) by region/age group. Patients who vomited are included. Median (horizontal line), box
(interquartile range) and whiskers represent the most extreme individual point which is not more than 1.5× the length of the box
Fig. 7 Summary of the observed ACPR28 by estimated artefenomel
concentration at day 7 together with the logistic regression model
predictions. The dots and error bars represent the observed ACPR28
with 90% CI for five artefenomel concentration bins (categories). The
lines represent the final logistic regression model predictions taking
into account the median artefenomel Cday7, as well as the median
piperaquine Cday7 and median baseline parasitaemia, for each bin.
Number of patients per bin: Africa≤ 5 years n = 53, Africa > 5 years
n = 15, Asia n = 20
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Figure 9 also shows the observed individual exposure
combinations flagged as Cure (open symbols) or Failure
(closed symbols). These exposures are associated with a
wide range of baseline parasitaemia levels. The data
points are the actual data used to estimate the model,
which is represented by the isoboles, and thus it is clear
which part of the isobole is supported directly by the
data and which is an extrapolation. For example, the
inference that in African patients for a baseline parasit-
aemia of 100,000 parasites/μL an artefenomel Cday7 of
8 ng/ml or higher (administered alone) is predicted to
have pACPR > 0.95 is an extrapolation, since there are
no patient data supporting this scenario.
Dose–response relationship
The projected ACPR28 simulations for various dose
combinations, taking into account between-subject
variability as well as model parameter uncertainty in
both PK and exposure response, are shown in Table 6.
The identified age effect on the relative bioavailability
of artefenomel was not included in the simulations.
Thus, hypothetically, if similar exposures to African
patients > 5 years were achieved in patients ≤ 5 years
(e.g. alternative formulation or alternative dose adjust-
ment), the doses highlighted in Table 6 may achieve an
ACPR28 > 95%. Note that the projections for several
dose combinations in the table are extrapolations from
the model, both the mono-therapy (exposure–response
component) and the higher dose levels (PK
component).
Discussion
We report the results of the first phase II dose-ranging
study to assess the potential of a single encounter cura-
tive treatment (artefenomel plus PQP) for uncompli-
cated P. falciparum malaria in adults and children in
Africa and Asia (Vietnam).
None of the treatment arms reached the pre-specified
target efficacy of ≥ 95% PCR-adjusted ACPR28 in the
overall population or in any of the subpopulations, in-
cluding African patients > 5 years of age, demonstrating
that a single encounter treatment with artefenomel
Fig. 8 Estimated exposure–ACPR28 relationship for the combination of artefenomel with piperaquine for a baseline parasitaemia of 10,000
parasites/μL. a African patients, b Vietnamese patients, 3D representation; blue highlights the ACPR28 > 0.95. The shaded area shows the
concentrations required to achieve a probability of ACPR28 > 0.95
Fig. 9 Concentrations associated with a probability of ACPR28 of 0.95:
model-predicted isobolograms by region and baseline parasitaemia.
Asian patients = red, African patients = blue. Baseline parasitaemia 10,000
parasites/μL, solid isobole; baseline parasitaemia 100,000 parasites/μL,
dotted isobole. Includes actual estimated individual exposures associated
with Cure (ACPR28), open symbol or Failure (recrudescence),
closed symbol
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800 mg plus up to 1440 mg PQP does not provide suffi-
cient exposure for a sufficient duration to achieve the re-
quired efficacy. Efficacy appeared lower in Vietnamese
than in African patients overall; however, the lowest effi-
cacy was observed among the youngest African age
group (> 0.5 to ≤ 2 years old).
The study was not powered to compare outcomes be-
tween treatment arms, and no clear PQP dose trend was
identified in the primary analysis for ACPR28. This was
due to large exposure variability and the limited dose
range studied, resulting in overlapping exposures be-
tween treatment arms, coupled with the binary nature of
the clinical endpoint. However, this large exposure range
allowed establishment of an exposure–response relation-
ship for both drugs in combination, which in turn
resulted in identification of factors influencing efficacy,
thereby providing a fuller understanding of the study
results.
Thus, the exposure–response analysis demonstrated
that both drugs contribute to efficacy (ACPR28) in a
concentration-dependent manner, and as might be
expected, higher baseline parasitaemia requires higher ex-
posures to provide the same ACPR28.
Within Africa, the concentration–response relation-
ship for artefenomel and piperaquine did not appear to
differ with age (or presumed immunity). While age was
not identified as a significant covariate for ACPR28, the
numbers of African patients > 5 years old was relatively
small and may have been insufficient to identify a differ-
ence. Instead, the lower efficacy in the youngest African
patients appeared due to lower exposure to artefenomel
(and to a lesser extent piperaquine). There was insuffi-
cient information to be able to identify the reason for
the lower exposure. This may have been a consequence
of incorrect dose adjustment to account for clearance/
bioavailability differences across the age range; however,
failure of the youngest children to consume the entire
dose (there were anecdotal reports of this despite high
reported compliance) or vomiting may have contributed.
The exposure–response analysis indicated that the
lower efficacy (ACPR28) in the Vietnamese relative to
the African population was due to lower sensitivity to
artefenomel (but not to piperaquine), that is, a regional
difference in the concentration–response relationship.
The mechanism of this lower sensitivity is not known.
Kelch13 genotyping indicated a high frequency of pa-
tients infected with artemisinin resistant parasites within
the Vietnamese sites. The most common Kelch13 geno-
types were C580Y, the predominant validated marker of
artemisinin resistance across the Greater Mekong
Subregion, and P553L, a candidate marker of artemisinin
resistance found in the Western Greater Mekong
Subregion [28].
Artemisinin resistance is characterised by a decrease
in the rate of parasite clearance following artemisinin
mono-therapy or artemisinin-containing combination
treatments in patients infected with parasites with muta-
tions in the Kelch13 gene [29]. In vitro this is manifested
by a decreased sensitivity to artemisinin of the early
rings stage of the parasite lifecycle [30], and as such is
considered partial resistance. Artemisinin partial resist-
ance has not been shown to reduce the cure rate unless
partner drug resistance is also present.
The current study is the first to fully evaluate the effi-
cacy of a combination containing a synthetic endoperox-
ide (artefenomel) in patients infected with artemisinin
resistant parasites, and the association between PCt1/2
following artefenomel/PQP treatment and Kelch13
mutation suggests that these mutations may drive a simi-
lar decrease in the rate of parasite clearance for
artefenomel-containing combinations as with artemisinin-
containing combinations [29]. In vitro data suggest that,
similar to DHA, there is reduced sensitivity of early mu-
tant rings to artefenomel [30]. However, Kech13 mutation
Table 6 Simulated % ACPR28 with 90% confidence intervals for single dose combinations of artefenomel and PQP in non-vomiting
African children ≤ 5 years old
PQP adult-equivalent dose, mg Artefenomel adult-equivalent dose, mg
0 200 400 800 1200 1600
0 NR (–) 22 (14–32) 39 (29–49) 70 (59–79) 86 (78–92) 94 (88–97)
320 27 (18–37) 35 (28–44) 52 (45–59) 79 (73–84) 91 (86–94) 96 (93–98)
640 40 (29–52) 48 (39–58) 64 (58–70) 85 (81–88) 94 (91–96) 97 (95–99)
960 51 (38–64) 59 (48–69) 72 (65–78) 89 (85–92) 95 (93–97) 98 (97–99)
1440 64 (49–76) 70 (59–80) 80 (73–86) 92 (89–95) 97 (95–98) 99 (98–99)
2000 74 (59–85) 79 (67–88) 86 (80–91) 95 (93–97) 98 (97–99) 99 (98–100)
2800 83 (70–91) 86 (76–93) 91 (85–95) 97 (95–98) 99 (98–100) > 99 (99–100)
3600 88 (78–95) 91 (83–96) 94 (90–97) 98 (96–99) 99 (99–100) > 99 (99–100)
For the stimulations, the identified age effect on artefenomel PK was not included; it was assumed, therefore, that exposures in the youngest patients were similar
to those in the older age groups. NR not reported
Predicted ACPR28 > 95%; outcome predicted with a lower bound > 95%
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was not identified as a significant covariate for ACPR28 in
the model. Caution should be exercised here, as the sam-
ple size may well not have been sufficient to identify any
association between Kelch13 and ACPR28 in the expos-
ure–response analysis.
High rates of DHA–piperaquine treatment failures are
now reported in the Greater Mekong Subregion, sug-
gesting co-segregation, or at least coexistence of artemi-
sinin and piperaquine resistance. Three of the four sites
in Vietnam involved in the study (Gia Lai, Binh Phauc
and Khanh Hoa) are located in provinces bordering
Cambodia, and so conceivably artemisinin and pipera-
quine resistant genes could coexist. It is noteworthy that
no difference was detected in the sensitivity (exposure–
response relationship) for piperaquine between Vietnam
and Africa. However, the sensitivity to piperaquine of P.
falciparum parasites collected in this study is not cur-
rently known. Recent work to identify genetic markers
of piperaquine resistance has confirmed that increased
copy numbers of plasmepsin 2 and plasmepsin 3 genes,
along with Pfmdr1 gene de-amplification, are independ-
ently associated with resistance to piperaquine, and that
these markers of piperaquine resistance are prevalent in
Cambodia and coexist with Kelch13 [31, 32]. We intend
to investigate the frequency of genetic markers of piper-
aquine resistance in samples collected during this study
and to investigate the relationship between Kelch13 and
genetic markers of resistance, and PCt1/2 and ACPR.
We are also currently investigating the efficacy of artefe-
nomel in combination with ferroquine. Both parent drug
and circulating active metabolite have significantly longer
half-life values than piperaquine, and hence this combin-
ation has a greater probability of achieving the target effi-
cacy. Ex vivo studies performed with Cambodian clinical
isolates suggest negligible impact of piperaquine resistance
on ferroquine potency [33].
The significant rate of vomiting and the high dosing
volume, particularly for young children, were problem-
atic and may have contributed to the lower drug expo-
sures in the youngest children. The development of
age-appropriate formulations is key to the success of
individual studies and to development programmes as a
whole. Asymptomatic QTc increases from baseline were
frequently reported as expected for PQP.
The study results also illustrate the challenges in de-
veloping a single encounter combination treatments.
Firstly, the administered dose needs to be higher to
achieve the required duration of exposure compared to
multiple day treatments; therefore, the ratio of Cmax to
overall exposure will be greater. Secondly, high between-
subject variability in drug exposures, due in part to a
limited number of body weight bands for dosing (and
which in this study may have been compounded by chal-
lenges in administering large dosing volumes to sick
children), in addition to a large between-subject variabil-
ity in baseline parasitaemia and potentially parasite sen-
sitivity, means that the majority of patients will be
required to be 'overdosed' if a very high cure rate is to
be achieved with a single (adult equivalent) dose level.
Both factors mean that a wide therapeutic window is
required.
Limitation of the study
A significant limitation of the study was that, although
the formulation used had been tested in adult healthy
subjects, it had not been tested in adult and, more im-
portantly, paediatric malaria patients. It is possible that
the palatability of the formulation and/or volume of ad-
ministration contributed to the higher than expected
rate of vomiting in the study. In addition, although com-
pliance data on drug consumption were collected, insuf-
ficient detail was recorded to truly capture compliance,
since despite a high reported success rate of drug admin-
istration, there were anecdotal reports that young chil-
dren were unable to ingest the full dose. The effect of
this was that the study was unable to conclude on the
best weight-based dose adjustment for patients weighing
< 35 kg; i.e. drug exposure in young children was lower
than in adults. However, it could not be concluded
whether this was due to the weight-based dose adjust-
ments or because the intended dosage was not success-
fully administered.
However, the dose–response simulations suggest that,
even if the young children had similar exposures to the
adults as well as no vomiting, the target efficacy would
not have been achieved.
Conclusions
None of the treatment arms reached the target efficacy
of > 95% PCR-adjusted ACPR at day 28. Achieving very
high efficacy following single dose treatment is challenging
since > 95% of the population must have sufficient concen-
trations to achieve cure across a range of parasite sensitiv-
ities and baseline parasitaemia levels, meaning that a
significant number of patients are 'overdosed'. Drugs with
a substantial therapeutic window are therefore required.
Projected single dose combination doses of artefenomel
plus PQP that may achieve the target efficacy in the Afri-
can population were not markedly higher than those
tested in this study, but are most likely not clinically viable
due to tolerability and practical dose size.
A high frequency of patients in Vietnam were infected
with artemisinin resistant parasites, and an association
between PCt1/2 following artefenomel/PQP treatment
and Kelch13 mutation suggests that these mutations
may drive a similar decrease in the rate of parasite clear-
ance for artefenomel-containing combinations as
observed with artemisinin-containing combinations [28].
Macintyre et al. BMC Medicine  (2017) 15:181 Page 16 of 19
While challenging, the development of tools suitable for
deployment as single encounter curative treatments for
adults, and particularly children in Africa, and to support
elimination strategies remains a key development goal.
There is currently no evidence that full artemisinin resist-
ance has emerged in Southeast Asia; i.e. there is no evi-
dence that reduced sensitivity of the early ring stage has
progressed to full resistance [28]. The results of the effi-
cacy study of artefenomel and ferroquine will inform us of
the potential of artefenomel-containing combinations to
treat malaria in both Africa and Southeast Asia where par-
tial resistance to artemisinin and resistance to piperaquine
is widespread.
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